US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Longeveron Inc. - Class A Common stock (NQ:LGVN)

1.670 -0.080 (-4.57%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Study Links Ramadan Fasting to Lower Risk of Chronic Disease Development
Via Investor Brand Network
News headline image
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society (ORS) 2024 Annual Meeting ↗
BioRestorative Therapies (NASDAQ: BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions such as obesity and... 
Via Benzinga
Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech’s Investigational Alzheimer’s Treatment Shows Positive Trial Results
--News Direct-- 
Via News Direct
News headline image
Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech's Investigational Alzheimer's Treatment Shows Positive Trial Results ↗
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to slow the effects of life-threatening and chronic aging-related conditions using cellular therapies, is making inroads with... 
Via Benzinga
Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association
Via Investor Brand Network
Five Significant Strides Made in Alzheimer’s Research in 2023
Via Investor Brand Network
News headline image
Why Longeveron (LGVN) Shares Are Falling Sharply ↗
Longeveron Inc (NASDAQ: LGVN) shares are trading lower by 22.8% to $1.25 Thursday morning after the company has finalized an agreement for a 
Via Benzinga
BioMedNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN)
Via Investor Brand Network
Topics Intellectual Property
Dietician Tips for Boosting Muscle Mass, Living Longer
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Granted US Patent Allowance for Key Technology Behind Lead Investigation Product
Via Investor Brand Network
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
Scientists Discover Alzheimer’s Can Be Categorized into Five Subtypes
Via Investor Brand Network
News headline image
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying ↗
The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Studies Suggest Fasting Could Tone Down Alzheimer’s Signs
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Enters Definitive Agreement for $2.36M Registered Direct Offering
Via Investor Brand Network
News headline image
Nasdaq Gains 100 Points; CarMax Earnings Top Views ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76.... 
Via Benzinga
Topics Stocks
News headline image
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Moves Lower; Micron Issues Strong Forecast ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.58% to 37,296.40 while the NASDAQ rose 0.77% to 14,891.87. The... 
Via Benzinga
Topics Stocks
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports Additional Positive Clinical Data, Imaging Biomarker Results in Phase 2a Lomecel-B(TM) Trial
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
Smart Trackers Could Detect Aging-Related Complications in Seniors
Via Investor Brand Network
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer’s Disease With Lomecel-B™
--News Direct-- 
Via News Direct
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™ ↗
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions using cell therapies, continues to make positive progress. 
Via Benzinga
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Eyes ‘Encouraging’ Results from CLEAR MIND Trial
Via Investor Brand Network
Hidden Belly Fat Could Be a Precursor of Alzheimer’s Onset Years Later
Via Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Encouraged by Positive Results from Phase 2a Trial in Patients with Mild AD; Explores Paths Forward for the Development of Lomecel-B(TM)
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >